{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:33:55Z","timestamp":1774265635485,"version":"3.50.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Hypothesis<\/jats:title>\n                  <jats:p>Antipsychotic (AP) prescription in clinical high risk for psychosis (CHR-P) subjects remains a divisive issue. Although official guidelines currently discourage AP treatment in CHR-P, it is common in clinical practice, especially for psychosis prevention. The aim of this study was to investigate whether baseline AP need (especially in high-dose) indexes a CHR-P subgroup with poorer prognosis and differs from AP-na\u00efve subjects in terms of sociodemographic, clinical, and outcome parameters across a 2-year follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>CHR-P participants were treated within an \u201cEarly Intervention in Psychosis\u201d program and completed the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF) scale both at baseline and every 12 months. Individuals with baseline AP prescription were included in the high-dose or low-dose CHR-P-AP+ subgroup. The others were grouped as AP-na\u00efve. Cox regression analyses and mixed-design ANOVA were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Results<\/jats:title>\n                  <jats:p>180 CHR-P individuals were enrolled (32 high-dose, 60 low-dose, and 88 AP-na\u00efve). Compared to AP-naive, CHR-P AP+ subgroups showed older age and more severe clinical presentation. High-dose subgroup also had grater functioning decline at entry and poorer functional recovery at follow-up. No inter-group differences in psychosis transition and symptomatic remission were found. Significant improvement in clinical outcomes were found over time in all subgroups. Baseline AP prescription was specifically associated with a more relevant improvement in PANSS total score, and in negative and disorganized symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that baseline AP need is an important prognostic parameter in CHR-P and should be considered in risk\/benefit calculators.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbae029","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:27:30Z","timestamp":1709274450000},"page":"432-445","source":"Crossref","is-referenced-by-count":11,"title":["Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4746-2061","authenticated-orcid":false,"given":"Lorenzo","family":"Pelizza","sequence":"first","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum\u2014Universit\u00e0 di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Di Lisi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum\u2014Universit\u00e0 di Bologna , Bologna ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Leuci","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Quattrone","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Azzali","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL-IRCCS di Reggio Emilia , Reggio Emilia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pupo","sequence":"additional","affiliation":[{"name":"Pain Therapy Service, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Paulillo","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Menchetti","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Pathological Addiction, Azienda USL di Parma , Parma ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"2025031503073951300_CIT0001","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.schres.2020.03.063","article-title":"Clinical high risk for psychosis in children and adolescents: a meta-analysis of transition prevalences","volume":"243","author":"Raballo","year":"2022","journal-title":"Schizophr Res."},{"issue":"2","key":"2025031503073951300_CIT0002","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jcpp.13438","article-title":"Editorial perspective: psychosis risk in adolescence\u2014outcomes, comorbidity, and antipsychotics","volume":"63","author":"Raballo","year":"2022","journal-title":"J Child Psychol Psychiatry."},{"issue":"1","key":"2025031503073951300_CIT0003","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41398-023-02405-6","article-title":"The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis","volume":"13","author":"Raballo","year":"2023","journal-title":"Transl Psychiatry."},{"issue":"16","key":"2025031503073951300_CIT0004","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1017\/S0033291720004237","article-title":"Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem","volume":"50","author":"Raballo","year":"2020","journal-title":"Psychol Med."},{"issue":"1","key":"2025031503073951300_CIT0005","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1017\/S0033291719003337","article-title":"Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis","volume":"52","author":"Raballo","year":"2022","journal-title":"Psychol Med."},{"issue":"3","key":"2025031503073951300_CIT0006","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jaac.2021.05.025","article-title":"Antipsychotics in children and adolescents at clinical high risk for psychosis","volume":"61","author":"Raballo","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"1\u20133","key":"2025031503073951300_CIT0007","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.schres.2010.10.028","article-title":"Follow-up of subjects with suspected pre-psychotic state in Taiwan","volume":"126","author":"Liu","year":"2011","journal-title":"Schizophr Res."},{"issue":"3","key":"2025031503073951300_CIT0008","doi-asserted-by":"publisher","first-page":"21m","DOI":"10.4088\/JCP.21m14092","article-title":"Antipsychotic exposure in clinical high risk of psychosis: empirical insights from a large cohort study","volume":"83","author":"Zeng","year":"2022","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"2025031503073951300_CIT0009","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/ijnp\/pyab030","article-title":"Negative prognostic effect of baseline antipsychotic exposure in Clinical High Risk for Psychosis (CHR-P): is pre-test risk enrichment the hidden culprit","volume":"24","author":"Raballo","year":"2021","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025031503073951300_CIT0010","volume-title":"Raccomandazioni regionali per la promozione della salute e del benessere in persone all\u2019esordio psicotico (ultimo aggiornamento: Agosto 2023)","author":"Gruppo regionale \u201cPercorsi Esordi Psicotici\u201d della Regione Emilia-Romagna (GRER)","year":"2023"},{"key":"2025031503073951300_CIT0011","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fpsyt.2019.00764","article-title":"Preventive treatments for psychosis: umbrella review (Just the Evidence)","volume":"10","author":"Fusar-Poli","year":"2019","journal-title":"Front Psychiatry."},{"issue":"3","key":"2025031503073951300_CIT0012","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.eurpsy.2015.01.013","article-title":"EPA guidance on the early intervention in clinical high risk states of psychoses","volume":"30","author":"Schmidt","year":"2015","journal-title":"Eur Psychiatry."},{"key":"2025031503073951300_CIT0013","volume-title":"Australian Clinical Guideline for Early Psychosis (updated in June 2016)","author":"Orygen, The National Centre of Excellence in Youth Mental Health","year":"2016"},{"issue":"9","key":"2025031503073951300_CIT0014","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/0706743717719895","article-title":"Canadian treatment guidelines for individuals at clinical high risk of psychosis","volume":"62","author":"Addington","year":"2017","journal-title":"Can J Psychiatry."},{"key":"2025031503073951300_CIT0015","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-023-02139-2","article-title":"Clinical High Risk for Psychosis (CHR-P) in children and adolescents: a roadmap to strengthen clinical utility through conceptual clarity","author":"Raballo","year":"2023","journal-title":"Eur Child Adolesc Psychiatry."},{"issue":"7","key":"2025031503073951300_CIT0016","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0004867420917449","article-title":"Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis)","volume":"54","author":"Zhang","year":"2020","journal-title":"Aust N Z J Psychiatry."},{"issue":"1","key":"2025031503073951300_CIT0017","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41537-022-00254-8","article-title":"Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision","volume":"8","author":"Zhang","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"2025031503073951300_CIT0018","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1017\/S0033291723002180","article-title":"Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis","volume":"53","author":"Raballo","year":"2023","journal-title":"Psychol Med."},{"issue":"4","key":"2025031503073951300_CIT0019","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00406-021-01331-2","article-title":"Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals","volume":"272","author":"Zhang","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"10","key":"2025031503073951300_CIT0020","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1017\/S0033291722001428","article-title":"Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis","volume":"53","author":"Raballo","year":"2023","journal-title":"Psychol Med."},{"issue":"1","key":"2025031503073951300_CIT0021","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/00048674211011243","article-title":"Antipsychotic treatment in clinical high risk for psychosis: iatrogenesis related to dopamine supersensitivity psychosis","volume":"56","author":"Bastiampillai","year":"2022","journal-title":"Aust N Z J Psychiatry."},{"issue":"5","key":"2025031503073951300_CIT0022","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/0004867420984836","article-title":"Antipsychotic treatment in clinical high risk for psychosis: protective, iatrogenic or further risk flag","volume":"55","author":"Raballo","year":"2021","journal-title":"Aust N Z J Psychiatry."},{"issue":"6","key":"2025031503073951300_CIT0023","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/eip.13399","article-title":"The \u201cParma At-Risk mental states\u201d (PARMS) program: general description and process analysis after 5 years of clinical activity","volume":"17","author":"Pelizza","year":"2023","journal-title":"Early Interv Psychiatry"},{"issue":"11\u201312","key":"2025031503073951300_CIT0024","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States","volume":"39","author":"Yung","year":"2005","journal-title":"Aust N Z J Psychiatry."},{"issue":"1","key":"2025031503073951300_CIT0025","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0920-9964(02)00167-6","article-title":"Psychosis prediction: 12-month follow up of a high-risk (\u201cprodromal\u201d) group","volume":"60","author":"Yung","year":"2003","journal-title":"Schizophr Res."},{"key":"2025031503073951300_CIT0026","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00406-023-01600-2","article-title":"Longitudinal evaluation on negative symptoms in young people at Ultra-High Risk (UHR) of psychosis: results from a 2-year follow-up study in a real-world care setting","volume":"273","author":"Pelizza","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"2025031503073951300_CIT0027","volume-title":"SCID-5-CV: intervista clinica strutturata per i disturbi del DSM-5, versione per il clinico","author":"First","year":"2017"},{"key":"2025031503073951300_CIT0028","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1192\/bjp.174.5.432","article-title":"Health of the Nation Outcome Scales (HoNOS). Glossary for HoNOS score sheet","volume":"174","author":"Wing","year":"1999","journal-title":"Br J Psychiatry."},{"issue":"2","key":"2025031503073951300_CIT0029","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"2025031503073951300_CIT0030","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"2016","edition":"5th ed"},{"key":"2025031503073951300_CIT0031","volume-title":"Traduzione e adattamento italiano della CAARMS (The Comprehensive Assessment of At-Risk Mental States)","author":"Raballo","year":"2013"},{"issue":"4","key":"2025031503073951300_CIT0032","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/eip.12669","article-title":"The approved Italian version of the comprehensive assessment of at-risk mental states (CAARMS-ITA): field test and psychometric features","volume":"13","author":"Pelizza","year":"2019","journal-title":"Early Interv Psychiatry"},{"issue":"2","key":"2025031503073951300_CIT0033","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000098491","article-title":"Discriminant ability and criterion validity of the HoNOS in Italian psychiatric residential facilities","volume":"40","author":"Gigantesco","year":"2007","journal-title":"Psychopathology."},{"issue":"7","key":"2025031503073951300_CIT0034","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/eip.13437","article-title":"A public early intervention approach to first-episode psychosis: treated incidence over 7 years in the Emilia-Romagna region","volume":"17","author":"Belvederi Murri","year":"2023","journal-title":"Early Interv Psychiatry"},{"issue":"8","key":"2025031503073951300_CIT0035","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.comppsych.2012.05.001","article-title":"Symptomatic and functional remission and its associations with quality of life in patients with psychotic disorder in Assertive Community Treatment teams","volume":"53","author":"Kortrijk","year":"2012","journal-title":"Compr Psychiatry."},{"key":"2025031503073951300_CIT0036","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2020.03.051","article-title":"Suicide risk in young people at Ultra-High Risk (UHR) of psychosis: findings from a 2-year longitudinal study","volume":"220","author":"Pelizza","year":"2020","journal-title":"Schizophr Res."},{"key":"2025031503073951300_CIT0037","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpsychires.2019.05.008","article-title":"Meta-analysis of the Positive and Negative Syndrome Scale (PANSS) factor structure","volume":"115","author":"Shafer","year":"2019","journal-title":"J Psychiatr Res."},{"issue":"3","key":"2025031503073951300_CIT0038","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry."},{"issue":"4","key":"2025031503073951300_CIT0039","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr Bull."},{"key":"2025031503073951300_CIT0040","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.schres.2021.12.025","article-title":"Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: a 1-year longitudinal study","volume":"241","author":"Azzali","year":"2022","journal-title":"Schizophr Res."},{"issue":"suppl 1","key":"2025031503073951300_CIT0041","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull."},{"issue":"3","key":"2025031503073951300_CIT0042","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00406-019-01018-9","article-title":"Anhedonia in adolescents at ultra-high risk (UHR) of psychosis: findings from a 1-year longitudinal study","volume":"270","author":"Pelizza","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"2025031503073951300_CIT0043","volume-title":"Statistical Package for Social Science (SPSS) 15.0 for Windows","author":"SPSS Inc","year":"2010"},{"issue":"5","key":"2025031503073951300_CIT0044","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.joca.2016.01.008","article-title":"Multiple P-values and Bonferroni correction","volume":"24","author":"Ranstam","year":"2016","journal-title":"Osteoarthritis Cartilage."},{"issue":"5","key":"2025031503073951300_CIT0045","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ki.2008.217","article-title":"The analysis of survival data: the Kaplan-Meier method","volume":"74","author":"Jager","year":"2008","journal-title":"Kidney Int."},{"issue":"4","key":"2025031503073951300_CIT0046","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bimj.201800275","article-title":"Cox regression model with randomly censored covariates","volume":"61","author":"Atem","year":"2019","journal-title":"Biom J"},{"issue":"6","key":"2025031503073951300_CIT0047","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/eip.13105","article-title":"Duration of untreated illness with obsessive-compulsive disorder in Japan","volume":"15","author":"Matsumoto","year":"2021","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"2025031503073951300_CIT0048","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1521\/suli.2007.37.3.248","article-title":"A revised nomeclature for the study of suicide and suicidal behaviors - Part 1: background, rationale and methodology","volume":"37","author":"Silverman","year":"2007","journal-title":"Suicide Life Threat Behav"},{"issue":"4","key":"2025031503073951300_CIT0049","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.rcp.2017.08.004","article-title":"Functional recovery in schizophrenia. Recuperaci\u00f3n funcional en la esquizofrenia","volume":"48","author":"Silva","year":"2019","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"},{"key":"2025031503073951300_CIT0050","doi-asserted-by":"crossref","DOI":"10.3109\/9780203501771","volume-title":"Treating Schizophrenia in the Prodromal Phase","author":"Yung","year":"2004"},{"issue":"2","key":"2025031503073951300_CIT0051","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/schbul\/22.2.283","article-title":"Monitoring and care of young people at incipient risk of psychosis","volume":"22","author":"Yung","year":"1996","journal-title":"Schizophr Bull."},{"issue":"8","key":"2025031503073951300_CIT0052","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/070674371005500803","article-title":"Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders","volume":"55","author":"McGorry","year":"2010","journal-title":"Can J Psychiatry."},{"issue":"11","key":"2025031503073951300_CIT0053","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1017\/S0033291717000319","article-title":"Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort","volume":"47","author":"Brucato","year":"2017","journal-title":"Psychol Med."},{"issue":"5","key":"2025031503073951300_CIT0054","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jcpp.13322","article-title":"Annual research review: prevention of psychosis in adolescents\u2014systematic review and meta-analysis of advances in detection, prognosis and intervention","volume":"62","author":"Catalan","year":"2021","journal-title":"J Child Psychol Psychiatry."},{"issue":"3","key":"2025031503073951300_CIT0055","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/eip.13145","article-title":"Personal health budget in patients with first episode psychosis: a new rehabilitation model based on a community care system in Italy","volume":"16","author":"Leuci","year":"2022","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"2025031503073951300_CIT0056","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-013-0046-1","article-title":"Antipsychotic interventions in prodromal psychosis: safety issues","volume":"27","author":"Liu","year":"2013","journal-title":"CNS Drugs"},{"issue":"6","key":"2025031503073951300_CIT0057","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/schbul\/sbr194","article-title":"Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals","volume":"38","author":"Allen","year":"2012","journal-title":"Schizophr Bull."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/432\/57119025\/sbae029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/432\/57119025\/sbae029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:07:53Z","timestamp":1742008073000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/51\/2\/432\/7637374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,29]]},"published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae029","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,29]]}}}